The Hyderabad-based drugmaker said consolidated net profit rose to Rs Rs 361 crore (Rs 3.61 billion) for the fiscal first quarter ended June, from Rs 336 crore (Rs 3.36 billion) a year earlier.
Dr Reddy's gets warning from US health regulator
Dr Reddy's Laboratories on Monday said it has, for the first time, started testing a drug in Europe with the initiation of Phase I clinical trials for its cardiovascular drug candidate RUS 3108 in Belfast, Ireland.
Dr Reddy's Laboratories Ltd on Friday said it has received tentative approval from US Food and Drug Administration for amlodipine besylate tablets.
Pharma major Dr Reddy's Laboratories, on Monday said it will offer MBA programme in pharma management for its employees in association with Narsee Monjee Institute of Management Studies, Mumbai.
Take the Rediff Biz Quiz and find out how much you know about India Inc's merger and acquisition operatiosns.
The Drug Controller General of India (DCGI) has sought clarification from pharma majors Dr Reddy's Laboratories and Mumbai-based Piramal Healthcare, for allegedly sponsoring doctors for conferences.
Dr Reddy's Laboratories Limited announced on Thursday that the United States Food and Drug Administration has issued final approval for the company's abbreviated New Drug Application for Ciprofloxacin tablets 100 mg, 250 mg, 500 mg and 750 mg.
For decades, multinational pharmaceutical companies and Indian drugmakers worked in ways that supported each other: MNCs brought innovation and brands, while Indian companies built scale through generics and cost efficiency. There was an important overlap - generic drugs - but this is shrinking fast. And the consequences are reshaping India's gigantic pharmaceutical market.
Sunovion Pharmaceuticals Inc is the owner of the Eszopiclone drug.
Hindustan Unilever (HUL) has topped the Perpetual Capital Hurun India Impact 50 - 2026 list with 53.9 points (on the scale of 0-100), reflecting a strong performance across key sustainable development goals (SDGs), including climate, water, circularity, gender and biodiversity.
The collaboration will work on a profit sharing model and entail licensing of manufacturing know-how of products by DRL, local manufacturing of products in Russia, co-development of high technology products and knowledge sharing between both parties at regular intervals.
Dr Reddys Laboratories surged in early trades on Friday on good buying support, but it slipped from the days high. The scrip of the local pharmaceutical major continued to witness volatility.
The ruling NDA alliance has secured a majority in the Rajya Sabha elections, winning key seats in Bihar, Odisha, and Haryana, while other candidates were elected unopposed across multiple states. The elections were marked by cross-voting allegations and political maneuvering.
The FDA has been tightening its monitoring of Indian pharma majors over compliance issues. Surprise plant inspections and import alerts have been frequent outcomes
Dr Reddy's Laboratories, the country's second biggest drug maker, revealed an unexpected consolidated net loss of Rs 522 crore in the October-December quarter, due to a writedown of intangible assets and goodwill in its German arm, Betapharm.
Asian markets were trading mixed with the Nikkei gaining after the US dollar strengthened against the yen.
Dr Reddy's Laboratories plans to brand its speciality drugs sold in the US. It will begin selling branded skin care products by year-end. The venture will be spearheaded by Promius Pharma, a wholly owned subsidiary of its US arm
The Rajya Sabha elections saw several candidates elected unopposed, including Sharad Pawar and Ramdas Athawale, while Bihar, Odisha, and Haryana prepare for contested elections.
Global drug maker Dr Reddy's Laboratories is adding 1,300 people this year, including about 350 through campus recruitment, according to Prabir Kumar Jha, DRL's senior vice-president and global chief.
Suit alleges fraud by hiding significant deficiencies in CGMP regulations enforced by US health regulator.
Dr Reddy's Laboratories on Saturday reported a 93.79 per cent increase in consolidated net profit at Rs 90.91 crore (Rs 909.1 million) for the second quarter ended September 30, 2005
The $66 million (Rs 272.8 crore) Leiner Health Products is likely to sue DRL for the early divorce (the agreement has lasted only four years) from the alliance.
Pharmaceutical major Dr Reddy's Laboratories Ltd on Tuesday said it will offer up to 13.5 million American Depositary Shares.
Analysts are eyeing bigger launches that will positively impact company's fortunes.
Dr Reddy's Laboratories Limited aims to increase the R&D spend on its three major research programmes, including the reverse cholesterol transport area, in a bid to come out with pathbreaking molecules in the next 7-10 years.
Security breach came days after the firm got approval to conduct trials for Covid-19 vaccine candidate Sputnik V.
The Sensex finished 38 points higher at 3,640 on Thursday. The Nifty closed with a gain of 12 points at 1,146.
Indian drug maker Dr Reddy's Laboratories said on Friday its fiscal 2003 profit fell 28 per cent, on lower sales of a Prozac generic drug to the key US market and slowing domestic sales.\n\n\n\n
After sealing the area of the nitrogen gas leak that left two persons dead, Dr Reddy's Laboratories (DRL) is to be served a notice on the incident that occured at its manufacturing plant at Bollaram on the outskirts of Hyderabad.
"Dr Manmohan Singh, soon after becoming the prime minister, had himself carried a small table for us to have tea comfortably at his Safdarjung Lane residence instead of asking his house help," Dr Srinath Reddy, who was the chairperson of the PM's medical panel, recalled.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances